Seeking Alpha: Receptos Could Meet With A More Positive Reception

Investors do well to be very skeptical of the biotech companies that go public in the late stages of a multi-year bull market. In many case...

Investopedia: Can Sanofi Investors Just Blame It On Rio?

Sanofi (NYSE: SNY ) was supposed to be a relatively solid Big Pharma company in 2013. True, the company is going through some pressures f...

Investopedia: Elan Shareholders Bring Management To Heel

Financial writers often lament that shareholders are too passive with respect to exercising their rights to oppose management decisions tha...

Investopedia: After A Good Run, Novartis Looks Fairly Valued

Like so many other pharmaceutical stocks, Novartis (NYSE: NVS ) has done pretty well for its shareholders over the past year and solidly be...

Investopedia: Elan Continues To Make Baffling Strategic Decisions

When Elan (NYSE: ELN ) announced back in February that it was selling its interests in Tysabri to Biogen Idec (Nasdaq: BIIB ) my biggest ...

Seeking Alpha: Alkermes Still Not Getting Full Credit For Its Pipeline

Biotech is a strange world, one where investors often seem to prefer stories that are relatively weak on sales, earnings, and actual data. ...